BBIO — BridgeBio Pharma Share Price
0.000.00%
Last trade - 00:00- $4.54bn
- $5.85bn
- $9.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 488.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -150.89% | ||
| Return on Equity | n/a | ||
| Operating Margin | -6528.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 40.56 | 8.25 | 69.72 | 77.65 | 9.3 | 169.28 | 193 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Directors
- Neil Kumar CEO (43)
- Brian Stephenson CFO (40)
- Charles Homcy CEX (72)
- Richard Scheller CEX (68)
- Michael Henderson OTH (31)
- Cameron Turtle OTH (31)
- Eric Aguiar IND (59)
- Jennifer Cook IND (55)
- Douglas Dachille IND (57)
- Ronald Daniels IND (61)
- Andrea Ellis IND (35)
- Fred Hassan IND (75)
- Andrew Lo IND (61)
- James Momtazee IND (49)
- Ali Satvat IND (43)
- Brenton Saunders IND (51)
- Randal Scott IND (63)
- Hannah Valantine IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 17th, 2019
- Public Since
- June 27th, 2019
- No. of Shareholders
- 72
- No. of Employees
- 550
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 183,703,641
- Address
- 3160 Porter Dr., Suite 250, PALO ALTO, 94304
- Web
- https://bridgebio.com/
- Phone
- +1 6503919740
- Auditors
- Deloitte & Touche LLP
Upcoming Events for BBIO
BridgeBio Pharma Inc Annual Shareholders Meeting
Q2 2024 BridgeBio Pharma Inc Earnings Release
Similar to BBIO
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the BridgeBio Pharma share price?
As of Today at 19:04 UTC, shares in BridgeBio Pharma are trading at $24.74. This share price information is delayed by 15 minutes.
How has the BridgeBio Pharma share price performed this year?
Shares in BridgeBio Pharma last closed at $24.74 and the price had moved by +50.21% over the past 365 days. In terms of relative price strength the BridgeBio Pharma share price has outperformed the S&P500 Index by +25% over the past year.
What are the analyst and broker recommendations for BridgeBio Pharma?
The overall consensus recommendation for BridgeBio Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BridgeBio Pharma dividend yield?
BridgeBio Pharma does not currently pay a dividend.
Does BridgeBio Pharma pay a dividend?
BridgeBio Pharma does not currently pay a dividend.
When does BridgeBio Pharma next pay dividends?
BridgeBio Pharma does not currently pay a dividend.
How do I buy BridgeBio Pharma shares?
To buy shares in BridgeBio Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BridgeBio Pharma?
As of the previous close price of $24.74, shares in BridgeBio Pharma had a market capitalisation of $4.54bn.
Where are BridgeBio Pharma shares listed?
Here are the trading details for BridgeBio Pharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BBIO
What kind of share is BridgeBio Pharma?
Based on an overall assessment of its quality, value and momentum BridgeBio Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BridgeBio Pharma share price forecast for 2024?
The analyst consensus target price for shares in BridgeBio Pharma is $49.00. That is 98.06% above the last closing price of $24.74.
Analysts covering BridgeBio Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$3.25 for the next financial year.
What is the trend in the BridgeBio Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BridgeBio Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -14.52%.
As of the last closing price of $24.74, shares in BridgeBio Pharma were trading -19.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BridgeBio Pharma PE Ratio?
The BridgeBio Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BridgeBio Pharma?
BridgeBio Pharma's management team is headed by:
- Neil Kumar - CEO
- Brian Stephenson - CFO
- Charles Homcy - CEX
- Richard Scheller - CEX
- Michael Henderson - OTH
- Cameron Turtle - OTH
- Eric Aguiar - IND
- Jennifer Cook - IND
- Douglas Dachille - IND
- Ronald Daniels - IND
- Andrea Ellis - IND
- Fred Hassan - IND
- Andrew Lo - IND
- James Momtazee - IND
- Ali Satvat - IND
- Brenton Saunders - IND
- Randal Scott - IND
- Hannah Valantine - IND